Spark Therapeutics (ONCE) Receives Overweight Rating from Cantor Fitzgerald

Share on StockTwits

Cantor Fitzgerald restated their overweight rating on shares of Spark Therapeutics (NASDAQ:ONCE) in a research note published on Thursday morning. The firm currently has a $80.00 target price on the biotechnology company’s stock, down from their prior target price of $103.00.

A number of other equities research analysts also recently issued reports on the stock. William Blair reiterated a buy rating on shares of Spark Therapeutics in a research note on Friday, September 21st. Raymond James reiterated a buy rating on shares of Spark Therapeutics in a research note on Friday, September 21st. Guggenheim initiated coverage on shares of Spark Therapeutics in a research note on Tuesday, October 9th. They set a buy rating and a $70.00 price objective on the stock. Zacks Investment Research downgraded shares of Spark Therapeutics from a buy rating to a hold rating in a research note on Saturday, October 13th. Finally, B. Riley upgraded shares of Spark Therapeutics from a neutral rating to a buy rating and increased their price objective for the stock from $68.00 to $71.00 in a research note on Wednesday, November 7th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company’s stock. Spark Therapeutics presently has a consensus rating of Buy and an average target price of $65.20.

Spark Therapeutics stock traded down $0.24 during trading hours on Thursday, reaching $43.36. 249,671 shares of the stock were exchanged, compared to its average volume of 522,954. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -5.68 and a beta of 1.98. The company has a quick ratio of 10.36, a current ratio of 10.71 and a debt-to-equity ratio of 0.09. Spark Therapeutics has a twelve month low of $34.53 and a twelve month high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.22). The firm had revenue of $10.70 million for the quarter, compared to analyst estimates of $27.44 million. Spark Therapeutics had a negative return on equity of 14.18% and a negative net margin of 127.82%. The company’s quarterly revenue was up 463.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.90) earnings per share. On average, sell-side analysts expect that Spark Therapeutics will post -1.53 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Teachers Advisors LLC raised its holdings in Spark Therapeutics by 1.4% in the 3rd quarter. Teachers Advisors LLC now owns 66,153 shares of the biotechnology company’s stock valued at $3,609,000 after buying an additional 917 shares during the last quarter. Vanguard Group Inc raised its holdings in Spark Therapeutics by 2.5% in the 3rd quarter. Vanguard Group Inc now owns 2,823,168 shares of the biotechnology company’s stock valued at $154,005,000 after buying an additional 67,846 shares during the last quarter. Marshall Wace North America L.P. bought a new position in Spark Therapeutics in the 3rd quarter valued at approximately $358,000. Marshall Wace LLP bought a new position in Spark Therapeutics in the 3rd quarter valued at approximately $2,253,000. Finally, Vanguard Group Inc. raised its holdings in Spark Therapeutics by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,823,168 shares of the biotechnology company’s stock valued at $154,005,000 after buying an additional 67,846 shares during the last quarter.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Read More: What is Compound Interest?

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Analysts Set Workday Inc  Price Target at $158.74
Analysts Set Workday Inc Price Target at $158.74
Lam Research Co.  Given Consensus Recommendation of “Buy” by Analysts
Lam Research Co. Given Consensus Recommendation of “Buy” by Analysts
Teck Resources  Shares Up 5.1%
Teck Resources Shares Up 5.1%
Five9  Trading Down 5.2%
Five9 Trading Down 5.2%
Albemarle  Releases FY 2019 Earnings Guidance
Albemarle Releases FY 2019 Earnings Guidance
Espers  Price Reaches $0.0001 on Major Exchanges
Espers Price Reaches $0.0001 on Major Exchanges


© 2006-2019 Ticker Report